FDA Approves Expanded Indication for Cerliponase Alfa to Treat CLN2 Disease in Children Under 3 Years

Published Date: 28 Jul 2024

The expanded indication, supported by a phase 2 open-label trial, includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or asymptomatic.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot